Adage Capital Partners’s ProQR Therapeutics PRQR Stock Holding History

Adage Capital Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.8M	Buy	9,015,897 +2,762,430	+44%	+$4.55M	0.02%	569
2026 Q1	$10.1M	Hold	6,253,467	–	–	0.02%	683
2025 Q4	$12.6M	Hold	6,253,467	–	–	0.02%	617
2025 Q3	$13.3M	Sell	6,253,467 -348,471	-5%	-$761K	0.02%	577
2025 Q2	$13.5M	Sell	6,601,938 -1,500,160	-19%	-$2.44M	0.02%	550
2025 Q1	$10.8M	Sell	8,102,098 -1,500,182	-16%	-$3.19M	0.02%	571
2024 Q4	$25.4M	Buy	9,602,280 +5,976,813	+165%	+$19M	0.04%	376
2024 Q3	$6.6M	Hold	3,625,467	–	–	0.01%	684
2024 Q2	$6.02M	Hold	3,625,467	–	–	0.01%	689
2024 Q1	$8.3M	Hold	3,625,467	–	–	0.02%	633
2023 Q4	$7.18M	Hold	3,625,467	–	–	0.01%	646
2023 Q3	$4.71M	Hold	3,625,467	–	–	0.01%	671
2023 Q2	$5.87M	Hold	3,625,467	–	–	0.01%	652
2023 Q1	$7.72M	Hold	3,625,467	–	–	0.02%	660
2022 Q4	$13.4M	Buy	3,625,467 +325,467	+10%	+$426K	0.03%	557
2022 Q3	$2.46M	Hold	3,300,000	–	–	0.01%	842
2022 Q2	$2.57M	Hold	3,300,000	–	–	0.01%	866
2022 Q1	$2.99M	Sell	3,300,000 -1,415,152	-30%	-$4.74M	0.01%	874
2021 Q4	$37.8M	Hold	4,715,152	–	–	0.07%	292
2021 Q3	$39.5M	Buy	4,715,152 +20,687	+0.4%	+$135K	0.08%	257
2021 Q2	$31.6M	Hold	4,694,465	–	–	0.06%	326
2021 Q1	$31M	Buy	4,694,465 +144,403	+3%	+$738K	0.06%	320
2020 Q4	$19.1M	Hold	4,550,062	–	–	0.04%	424
2020 Q3	$21.8M	Hold	4,550,062	–	–	0.05%	352
2020 Q2	$27.7M	Hold	4,550,062	–	–	0.07%	305
2020 Q1	$25M	Sell	4,550,062 -21,257	-0.5%	-$163K	0.07%	273
2019 Q4	$45.3M	Buy	4,571,319 +835,812	+22%	+$6.51M	0.11%	225
2019 Q3	$21.5M	Hold	3,735,507	–	–	0.05%	349
2019 Q2	$34M	Hold	3,735,507	–	–	0.08%	266
2019 Q1	$51.8M	Hold	3,735,507	–	–	0.13%	194
2018 Q4	$58.9M	Buy	3,735,507 +273,566	+8%	+$5.02M	0.16%	164
2018 Q3	$67M	Buy	3,461,941 +1,299,414	+60%	+$13.8M	0.15%	172
2018 Q2	$15.8M	Buy	2,162,527 +662,527	+44%	+$3.34M	0.04%	464
2018 Q1	$4.61M	Buy	1,500,000 +500,000	+50%	+$1.61M	0.01%	644
2017 Q4	$3.23M	Buy	+1,000,000	New	+$3.59M	0.01%	649

Other funds holding PRQR

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Adage Capital Partners's PRQR Position: Q2 2026 in Review

Adage Capital Partners increased its ProQR Therapeutics (PRQR) stake by 44% in Q2 2026, buying an estimated $4.55M and bringing the position to 9,015,897 shares worth $16.8M. The position accounts for 0.02% of the portfolio, ranked #569.

Adage Capital Partners first reported a position in PRQR in Q4 2017 and has held it in 35 quarters since. The position peaked at $67M in Q3 2018. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Adage Capital Partners held 9,015,897 shares of ProQR Therapeutics worth $16.8M as of Q2 2026.
Adage Capital Partners bought 2,762,430 ProQR Therapeutics shares in Q2 2026, an estimated $4.55M.
ProQR Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #569 holding.
Adage Capital Partners first reported a position in ProQR Therapeutics in Q4 2017 and has held it in 35 quarters since.
Adage Capital Partners's ProQR Therapeutics position peaked at $67M in Q3 2018.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.